Clinical trial

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

NCT06121557

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-11-01

PhasePHASE1

Study timeline

Study start (estimated)2023-11-01Date precision: day

Registry last updated2023-11-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Neoplasmsunresolved

Interventions

Surgery for harvesting tumor-draining lymph nodesPROCEDURE

CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide

FludarabineDRUG · verified · RxNorm: fludarabine

Tumor-draining lymph node-derived lymphocyte (LNL)BIOLOGICAL

Interleukin-2BIOLOGICAL

CamrelizumabBIOLOGICAL

Chemotherapeutic drug, ADC or PARP inhibitorDRUG

Sponsors & collaborators

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universitylead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06121557 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.